Clinical trial
A Prospective Study of Peginterferon Alfa-2a and Ribavirin: Outcomes Assessment in Chronic Hepatitis C Patients
NCT02850289 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective Study of Peginterferon Alfa-2a and Ribavirin: Outcomes Assessment in Chronic Hepatitis C Patients
- Lead sponsor
- Hoffmann-La Roche
- Phase
- Observational
- Overall status
- Completed
- Start date
- April 30, 2006
- Completion date
- October 31, 2008
- Enrollment
- 385 (actual)
- Sites
- 46
Conditions
As the registry lists them; a condition with its own page is linked.